CTNI-39. PHASE 1B CLINICAL TRIAL OF OKN-007 IN RECURRENT MALIGNANT GLIOMA

BACKGROUND: The nitrone compound OKN-007 is a novel anti-cancer agent. In glioblastoma xenografts, OKN-007 reduces cell proliferation and angiogenesis, and increases apoptosis. Here we report on the safety, efficacy, and pharmacokinetics (PK) of OKN-007 in adults with recurrent glioma. METHODS: NCT0...

Cijeli opis

Spremljeno u:
Bibliografski detalji
Izdano u:Neuro Oncol
Glavni autori: Battiste, James, Ikeguchi, Alexandra, Woo, Sukyung, Sharan, Satish, Zhao, Yan, Cohoon, Andrew, Sung, Sarah, Wright, Deborah, Teague, April, Jensen, Randy, Kim, Eun Ha, Yang, Won, Towner, Rheal
Format: Artigo
Jezik:Inglês
Izdano: Oxford University Press 2020
Teme:
Clinical Trials: Non-Immunologic
Online pristup:https://ncbi.nlm.nih.gov/pmc/articles/PMC7650506/
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1093/neuonc/noaa215.206
Oznake: Dodaj oznaku
Bez oznaka, Budi prvi tko označuje ovaj zapis!

Similar Items